

Expert Meeting on Access to Hepatitis B and C Treatment

Casablanca, Morocco, 12 – 14 December 2018

The Chief Executive Officer, DRAP attended the expert meeting on Access to Hepatitis B and C Treatment held in Casablanca, Morocco. As indicative from WHO surveillance reports, Pakistan has the second highest rate in Hepatitis C prevalence after Egypt. In this meeting, CEO DRAP shared Pakistan's experience for successful model of local manufacturing of new drugs i.e. Direct Acting Antivirals (DAAs) used in the treatment of Hepatitis B & C Treatment.

During the proceedings of the expert meeting a global, regional and national overview of Hepatitis was presented. In addition to it, various aspects for ensuring access of hepatitis treatment such as price reduction strategies for HBV/ HCV diagnostics and treatment, strategies for local production and intellectual property safeguards, and generics, quality and efficient public procurement.





